Home Page for Stem Cell Transplantation Therapy, MS, Parkinson's Treatment, Cord Blood, Stem Cell Research

Treatment with Adult and Cord Blood Stem Cells

Stem Cells for Hope, Inc. has an International Network of Clinics that are currently providing treatment programs for patients using Stem Cell solutions which contain your own Adult Stem Cells or harvested Cord Blood Stem Cells and a proprietary Stem Cell Biological solution for people suffering with neuro-degenerative diseases and physiological injuries. The conditions that are currently being treated at our Clinics are:

* Multiple Sclerosis
* Stroke
* Parkinson’s
* Muscular Dystrophy
* Cerebral Palsy
* Macular Degeneration
* Glaucoma
* Optic Nerve Damage
* Retinitis Pigmentosa
* Corneal Regeneration
* Diabetes Type I
* Hepatitis C
* Liver Cirrhosis
* Other medical conditions are evaluated for treatment on a Per Case Basis.

Please go to our “Contact Us” page or call us directly at (631) 929-3900
Become a Stem Cell VIP (Very Informed Patient):

Stem Cells for Hope's goal is to help educate you (the Patient) with important information about the use of Adult Stem Cells, Cord Blood Stem Cells, Embryonic and Fetal Stem Cells. We will also provide you with a fare assessment of the various types of treatment protocols that are available in other countries. Stem Cells for Hope is a US based company with a Global Network of treatment Clinics around the world. As a VIP, you can now make an educated choice of the treatments that are available to help achieve a “Better Quality of Life” for you and your loved ones.

Top
Conditions Treated With Stem Cells:

Top
Our Medical Evaluation Process:

These techniques developed by the Stem Cells for Hope Clinics are being applied to implement treatments for a wide range of human degenerative and debilitating conditions, including neurodegenerative diseases, ocular disease and various physiological injuries. Our Global Network of Clinics, who have been treating patients for the last 15 to 18 years, are also involved in ongoing human Stem Cell Research and the Development of new Stem Cell Transplantation Therapy protocols and they are currently successfully treating patients with this Regenerative Medical technology outside of the United States.

Stem Cells for Hope does not have any treatment facilities nor do we treat any patients inside the United States or any other countries where Stem Cell Transplantation Therapy is not approved by the local Government Health Administration.

Please see the Stem Cells for Hope [Medical Forms] for a checklist of medical information that we will require.

Our experienced International Medical and Scientific Board of Advisors will review all the material and provide us with a recommendation if the prospective patient is a good candidate for stem cell transplantation therapy. If so, they will then recommend a personalized treatment plan based on the patient’s medical history and current condition. We will then contact the prospective patient and begin the process of reporting their findings, send out the necessary forms and begin scheduling the treatment at the appropriate time and at the best affiliate clinic location based on their medical requirements.

It is important for any potential patient to receive the treatment as soon as possible after any accident or injury occurs or any degenerative disease is detected. This early intervention increases your chances of responding to the therapy and recovery rather than allowing the condition to degenerate further over time. However, the stem cell transplantation therapy has been successful as well on older patients we have treated (65 to 78 years of age) with a long history of degenerative diseases, injuries to the brain or the body.

Top
Medical Authorization:

When you decide to proceed further please contact us via phone or email and we will send you the appropriate Medical Authorization forms and our HIPPA compliance policy form that will allow us to receive copies of your medical records and share them with our Medical Advisors and Treating Physicians. These forms will also protect the confidentiality of your medical data and of the sharing of your information outside of the company. In addition, we will send you a more detailed checklist of the type of medical information and test results that we may require in order to do a proper evaluation of your current condition.

Please continue to navigate our website to learn more about Stem Cells, the science of Regenerative Medicine and our specific Adult Stem Cell and Cord Blood Stem Cell treatment protocols and patient testimonials.

Sincerely,


Peter K. Sidorenko
Chief Operating Officer
Stem Cell for Hope, Inc.


Direct: (631) 929-3900
Fax: (631) 929-3909


PeterK@stemcellsforhope.com

Multiple Sclerosis research study

This study is open for enrollment until December 1, 2009. The information below can be printed or call the numbers listed.

If you have a Spinal Cord Injury or Multiple Sclerosis You may be eligible for a research study Care Call is a phone-based intervention that aims to reduce health problems and improve quality of life for people with SCI or MS. You may be able to take part if you:  are an English-speaking adult who has SCI or MS  normally use a wheelchair during the day for 6 or more hours  do not currently have a deep wound  have access to a telephone for the next 6+ months  You will not need to travel to take part in this study; you may stay in your home.  You will receive $100 for your participation and completion of the study. For more information and to be screened for eligibility please call Kelsey Dicker 866-785-7040 (toll-free) You are welcome to share this form with others who might be eligible and interested to learn more about Care Call. Care Call is conducted by the New England Regional Spinal Cord Injury Center in Boston, MA and is funded by the Centers for Disease Control and Prevention (CDC) Award #R01/DD000155-01

---

Do you have a Spinal Cord Injury
or Multiple Sclerosis?
If so, you may be eligible for a research study!
Am I eligible to participate?
You may be able to take part if…
 You are an English-speaking adult who has SCI or MS and lives at home
 You normally use a wheelchair during the day for 6 or more hours
 You do not currently have a deep wound
 You will have access to a telephone for the next 6+ months
What is the study? How does the study work?
• Care Call, a phone-based intervention, aims to reduce health problems and improve quality of life for people with SCI or MS.
• You will not need to travel to take part in this study; you may stay in your home.
• If you choose to take part and are eligible for the study, you will be randomly assigned to either Group 1 or 2. Both groups will receive an in-home assessment at the beginning and end of the study, as well as a community resource book. Only Group 1 will receive weekly phone calls from the Care Call system.
• You will receive $100 for your participation and completion of the study.

I’m interested in participating! Who do I contact?
Please call Kelsey Dicker at (617) 638-1996 or toll-free at (866) 785-7040
to receive further information and to be screened for eligibility.
We look forward to hearing from you!

You are welcome to share this flyer with others who might be eligible and interested to learn more about Care Call.
Care Call is run by Steve Williams, MD, at the New England Regional Spinal Cord Injury Center in Boston, MA. The study is funded by the Centers for Disease Control and Prevention (CDC), Award ##R01/DD000155-01. This study is completely voluntary and will not affect any medical care you now receive.





Interested in learning more about
Education Programs &/or Research Projects?
This is information we need.

Name _____________________ Phone _____________________ Best time to call _____________________ Email _____________________ Research _____________________ Education _____________________

Fampridine-SR

Fampridine-SR is a sustained-release tablet formulation of the investigational drug fampridine (4-aminopyridine, or 4-AP). Data collected in laboratory studies found that fampridine can improve the communication between damaged nerves, which may result in increased neurological function.


Positive vote by FDA advisory committee for Fampridine-SR
Acorda Therapeutics, Inc. has announced the U.S. Food and Drug Administration (FDA) Peripheral and Central Nervous System Drugs (PCNSD) Advisory Committee voted 12 to 1 that clinical data on Fampridine-SR 10 mg twice daily demonstrated substantial evidence of effectiveness as a treatment to improve walking in people with multiple sclerosis (MS) and voted 10 to 2 (1 abstention) that it is clinically meaningful and can be safe for use.

"We are pleased with the outcome of today`s Advisory Committee meeting. People with MS have an urgent need for therapies to improve their walking, which is essential to conducting their activities of daily life. If approved, Fampridine-SR would be the first medicine to improve walking in people with MS," said Ron Cohen, M.D., Acorda Therapeutics President and CEO. "This Advisory Committee meeting is an important milestone in the development of Fampridine-SR, and we look forward to working with the FDA as it completes its review of Acorda`s New Drug Application."

The Committee also recommended by a vote of 12 to 1 that Acorda be required to evaluate the effects of doses lower than 10 mg twice daily, but by a 10 to 2 vote (1 abstention) that these studies not be required prior to approval.

At the request of the FDA, the Committee discussed possible conditions for use, including for patients with renal impairment or history of seizure. Acorda has proposed a Risk Evaluation and Mitigation Strategy (REMS) program, which could include healthcare professional and patient education around appropriate use of Fampridine-SR.

The FDA seeks the advice of an advisory committee such as the PCNSD when evaluating a potential new treatment, but is not required to follow its recommendation. The current Fampridine-SR Prescription Drug User Fee Act (PDUFA) date set by the FDA is October 22, 2009; the PDUFA date is the target date for the FDA to complete its review of Fampridine-SR.